Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 312 participants.

Also called NCT03770728

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 312 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03770728
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, China, Taiwan (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03770728. Randomized; quadruple masking; primary purpose treatment. Start 2019-08-01 (actual); primary completion 2020-11-28 (actual). Results posted on 2021-12-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea
Acronym
AMPLITUDE-S
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Efpeglenatide SAR439977
Intervention (Drug)
Placebo
Intervention (Drug)
Background therapy: Metformin alone or in combination with SU
Lead sponsor
Sanofi (class: industry)
Collaborator
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct03770728
Content hash
6dec067cf1b5625d44f5027dc18f261d6eb5f511db350b1abb35842312c2fae9